

## Contents

### Clinical Studies

- 363 The Amount and Concentration of Drain Amylase Together Predict Postoperative Pancreatic Fistula after Gastric Cancer Surgery More Accurately than the Concentration Alone**  
Miura, S. (Osaka/Hyogo); Wakahara, T.; Yamauchi, S.; Yasuhara, Y.; Mukubo, H.; Kanemitsu, K.; Iwasaki, T.; Sasako, M. (Osaka); Kakeji, Y. (Hyogo)
- 370 Poor Treatment Outcomes with Second-Line Chemotherapy in Advanced Synovial Sarcoma**  
Kojima, Y.; Shimoi, T.; Seo, T.; Yazaki, S.; Okuya, T.; Ohtake, Y.; Okuma, H.S. (Chuo-ku); Shimomura, A. (Chuo-ku/Shinjuku-ku); Nishikawa, T.; Tanioka, M.; Sudo, K.; Noguchi, E.; Tamura, K.; Yoshida, A.; Iwata, S.; Kobayashi, E.; Kawai, A.; Fujiwara, Y.; Yonemori, K. (Chuo-ku)
- 376 Effect of Germline MEFV Polymorphisms on the Prognosis of Japanese Children with Cancer: A Regional Analysis**  
Hasegawa, M.; Fukushima, H.; Suzuki, R.; Yamaki, Y.; Hosaka, S.; Inaba, M. (Tsukuba); Nakao, T. (Tsukuba/Saitama); Kobayashi, C. (Tsukuba/Mito); Yoshimi, A.; Tsuchida, M.; Koike, K. (Mito); Fukushima, T. (Tsukuba/Saitama); Takada, H. (Tsukuba)
- 384 Risk Factors for Nab-Paclitaxel and Gemcitabine-Induced Peripheral Neuropathy in Patients with Pancreatic Cancer**  
Catalano, M. (Florence); Ramello, M. (Trieste); Conca, R. (Rionero, Vulture); Aprile, G. (Vicenza); Petrioli, R. (Siena); Roviello, G. (Florence)
- 392 Immunogenicity of COVID-19 Vaccination in Melanoma Patients under Immune Checkpoint Blockade**  
Niewolik, J.; Mikuteit, M.; Cossmann, A. (Hannover); Vahldiek, K. (Wolfenbüttel); Gutzmer, R. (Minden); Müller, F.; Schröder, D.; Heinemann, S. (Göttingen); Behrens, G.M.N. (Hannover/Hannover-Braunschweig); Dopfer-Jablonka, A. (Hannover/Hannover-Braunschweig); Steffens, S.; Grimmelmann, I. (Hannover)

### Research Article

- 399 Extracellular Regucalcin Suppresses the Growth, Migration, Invasion, and Adhesion of Metastatic Human Prostate Cancer Cells**  
Yamaguchi, M. (Honolulu, HI); Murata, T. (Nagoya); Ramos, J.W. (Honolulu, HI)

### Short Communication

- 413 Comprehensive Analysis of Ixazomib-Induced Adverse Events Using the Japanese Pharmacovigilance Database**  
Yamaoka, K.; Fujiwara, M. (Kobe); Uchida, M. (Kyotanabe); Uesawa, Y. (Tokyo); Muroi, N.; Shimizu, T. (Kobe)

Cover illustration  
© S. Karger AG, Basel

Karger 

© 2022 S. Karger AG, Basel

Access to full text and tables of contents,  
including tentative ones for forthcoming issues:  
[www.karger.com/ocl](http://www.karger.com/ocl)